Problem

Healthcare organizations face a persistent capacity problem: clinicians and care teams cannot personally complete every follow-up, screening, medication check, or risk assessment. Hippocratic AI targets these resource gaps with non-diagnostic outreach that expands access without requiring an equivalent increase in clinical staffing. The economic case is tied to higher team capacity, fewer readmissions, recovered care-gap revenue, and an average reported 12x ROI across deployments.

The clearest use case is high-volume patient outreach by phone, particularly post-discharge recovery. An agent can check medication adherence, monitor symptoms, support pneumonia or joint-replacement recovery, and escalate concerning symptoms to a human nurse. This turns routine but clinically important work that often goes undone into a scalable prevention and care-management workflow.

Product / Service

Hippocratic AI provides safety-focused, patient-facing generative AI agents for health systems, payors, and pharmaceutical companies. The agents conduct natural, empathetic, non-diagnostic conversations—primarily by phone—then pull target populations from a customer’s systems and write outcomes back into the EHR or CRM. Pricing scales with call volume and use case, making the product an enterprise workflow service rather than a consumer chatbot.

Its core technology is Polaris, a safety-focused LLM constellation designed for long, multi-turn healthcare conversations. Hippocratic says agents are tested by thousands of licensed clinicians across hundreds of thousands of test calls, use specialized models to improve accuracy, and escalate to human nurses when necessary. The company also offers an agent-app-store model in which clinicians can create and shape specialized agents, which Hippocratic certifies before customer deployment.

Market

Hippocratic AI competes in the emerging market for patient-facing clinical AI agents, healthcare workforce augmentation, and automated care-management outreach. Its positioning is narrower and more safety-intensive than general-purpose conversational AI: the company focuses on non-diagnostic clinical workflows such as discharge follow-up, screening, annual-wellness outreach, chronic-care management, and care-gap closure. Adjacent competitors include Memora Health in automated care workflows, Hyro in health-system patient access, and broader healthcare automation platforms such as Commure, EliseAI, and Notable Health.

The company is not pre-revenue in the sense of being limited to an uncommercialized prototype. Hippocratic reports partnerships with more than 50 enterprise healthcare organizations, deployments in multiple countries, more than 200 million real interactions, and more than 1,000 available agents. It raised $126 million in Series C financing at a reported $3.5 billion valuation, bringing total funding to $404 million; the available research does not disclose revenue, but the customer contracts, volume-based pricing, and reported deployment outcomes indicate substantial commercial traction.